CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1. 2007

Alonso Heredia, and Bruce Gilliam, and Anthony DeVico, and Nhut Le, and Douty Bamba, and Robin Flinko, and George Lewis, and Robert C Gallo, and Robert R Redfield
Institute of Human Virology, University of Maryland, 725 W. Lombard Street, Baltimore, MD 21201, USA.

OBJECTIVE Studies in cell lines have demonstrated that CCR5 coreceptor levels influence the replication efficiency and Enfuvirtide (T-20) susceptibility of R5 HIV-1 strains. At present, however, the role that CCR5 levels on primary CD4 T cells--which are markedly lower than in cell lines and vary only approximately fivefold among most donors--may play in virus replication levels or susceptibility to T-20 is not known. In the present study we evaluated the impact of differences in CCR5 levels among donor CD4 T cells on the infection efficiency and T-20 susceptibility of R5 HIV-1. METHODS CD4 and CCR5 density levels were determined by Quantitative FACS analysis. Virus infectivity assays were conducted in cell lines and primary cells. Associations between coreceptor density, virus replication and T-20 sensitivity were tested using the Spearman's correlation test. RESULTS We found a positive correlation (r, 0.55; P = 0.011) between CCR5 density levels on primary CD4 T cells and replication of R5 HIV-1. In cell lines expressing physiologically relevant levels of CD4 and CCR5, T-20 was significantly more potent in cells with low CCR5 levels. In addition, T20 50% inhibitory concentrations for R5 HIV-1 replication varied approximately 100-fold among primary cells from different donors and they were positively correlated with CCR5 density values (r, 0.84; P = 0.00004). CONCLUSIONS These results suggest that CCR5 density levels in HIV-1 patients may impact the activity of T-20 against R5 strains and that therapeutic approaches to alter CCR5 density may potentiate T-20.

UI MeSH Term Description Entries
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077560 Enfuvirtide A synthetic 36-amino acid peptide that corresponds to the heptad repeat sequence of HIV-1 gp41. It blocks HIV cell fusion and viral entry and is used with other anti-retrovirals for combination therapy of HIV INFECTIONS and AIDS. DP 178,DP-178,DP178,Fuzeon,Pentafuside,Peptide T20,T20 Peptide,T20, Peptide
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015700 HIV Envelope Protein gp41 Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING. Envelope Protein gp41, HIV,HIV Transmembrane Protein gp41,HTLV-III gp41,env Protein gp41, HIV,gp41(HIV),gp41 Envelope Protein, HIV
D019713 Receptors, CCR5 CCR receptors with specificity for CHEMOKINE CCL3; CHEMOKINE CCL4; and CHEMOKINE CCL5. They are expressed at high levels in T-LYMPHOCYTES; B-LYMPHOCYTES; MACROPHAGES; MAST CELLS; and NK CELLS. The CCR5 receptor is used by the HUMAN IMMUNODEFICIENCY VIRUS to infect cells. Antigens, CD195,CC Chemokine Receptor 5,CCR5 Receptors,CD195 Antigens,CC-CKR5,CCR5 Receptor,CKR5 Receptors,Receptors, CKR5,Receptor, CCR5

Related Publications

Alonso Heredia, and Bruce Gilliam, and Anthony DeVico, and Nhut Le, and Douty Bamba, and Robin Flinko, and George Lewis, and Robert C Gallo, and Robert R Redfield
November 2005, Journal of acquired immune deficiency syndromes (1999),
Alonso Heredia, and Bruce Gilliam, and Anthony DeVico, and Nhut Le, and Douty Bamba, and Robin Flinko, and George Lewis, and Robert C Gallo, and Robert R Redfield
May 2024, AIDS (London, England),
Alonso Heredia, and Bruce Gilliam, and Anthony DeVico, and Nhut Le, and Douty Bamba, and Robin Flinko, and George Lewis, and Robert C Gallo, and Robert R Redfield
September 2001, Proceedings of the National Academy of Sciences of the United States of America,
Alonso Heredia, and Bruce Gilliam, and Anthony DeVico, and Nhut Le, and Douty Bamba, and Robin Flinko, and George Lewis, and Robert C Gallo, and Robert R Redfield
February 2002, Nature medicine,
Alonso Heredia, and Bruce Gilliam, and Anthony DeVico, and Nhut Le, and Douty Bamba, and Robin Flinko, and George Lewis, and Robert C Gallo, and Robert R Redfield
May 2015, Microbes and infection,
Alonso Heredia, and Bruce Gilliam, and Anthony DeVico, and Nhut Le, and Douty Bamba, and Robin Flinko, and George Lewis, and Robert C Gallo, and Robert R Redfield
January 2015, PloS one,
Alonso Heredia, and Bruce Gilliam, and Anthony DeVico, and Nhut Le, and Douty Bamba, and Robin Flinko, and George Lewis, and Robert C Gallo, and Robert R Redfield
April 2014, Immunology,
Alonso Heredia, and Bruce Gilliam, and Anthony DeVico, and Nhut Le, and Douty Bamba, and Robin Flinko, and George Lewis, and Robert C Gallo, and Robert R Redfield
January 2008, PloS one,
Alonso Heredia, and Bruce Gilliam, and Anthony DeVico, and Nhut Le, and Douty Bamba, and Robin Flinko, and George Lewis, and Robert C Gallo, and Robert R Redfield
July 1999, AIDS research and human retroviruses,
Alonso Heredia, and Bruce Gilliam, and Anthony DeVico, and Nhut Le, and Douty Bamba, and Robin Flinko, and George Lewis, and Robert C Gallo, and Robert R Redfield
June 2006, AIDS (London, England),
Copied contents to your clipboard!